SOURCE: Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc.

October 17, 2014 09:00 ET

Plandai Biotechnology Marketing of First Product to Customers Should Be a Cinch With Proven Higher Bioavailability

NEW YORK, NY--(Marketwired - October 17, 2014) - Plandaí Biotechnology (OTCQB: PLPL) began to lay out its initial plan this week explaining just how the company will get its first product, a green tea extract, into the hands of distributors once production begins at its facility in South Africa by the end of 2014. The company announced that it will first ship samples of its Phytofare Catechin Complex, to a list of potential customers worldwide. Plandaí's samples will be part of a package of information that will include the green tea product, brochures, a product profile, and most importantly, the preliminary results from a recent clinical trial, safety data, and stability data (shelf life).

It is that preliminary clinical trial data from a recent study performed by Professor Anne Grobler and her team at North West University in South Africa that should seal the deal with manufacturers and distributors worldwide, and those results should make marketing the company's Phytofare product an easy sell.

After all, that human clinical trial compared Plandaí's green tea extract with that of a commercially available extract and preliminary data showed that all 8 of the plant's catechins were detected in the bloodstream compared to just 2 from the generic extract, absorption of those catechins was 5 times greater, and the life span of the catechin's molecules in the bloodstream was doubled in Phytofare when compared to that of the commercial green tea extract. The result is that Plandaí will deliver a green tea extract that is ten times more bioavailable than a generic extract, and to an end user, that's exactly what they're looking for in nutraceutical products.

Plandaí says it has contracted with various distributors covering both North America and Europe who have been reaching out to their customers for over a year now and soliciting Plandaí's product. Armed with the aforementioned clinical trial data, distributors should find that their customer's level of interest will grow.

With consumers becoming more aware of the ingredients in their favorite health products, bioavailability is now a key concern within the nutraceutical marketplace. Purity no longer suffices as consumers are now acutely aware that no matter how pure something is, if it doesn't actually benefit your body, then they're essentially wasting their money.

Callum Bayliss-Duffield, Plandaí Biotechnology's Global Director of Marketing and Sales, said, "What this means for manufacturers is that they are now having to source ingredients that actually have a clinical effect on the body. The catch here is that the only way to know that an ingredient has a clinical effect on the body is to undertake human clinical trials (Phase 2). However there are very few ingredients on the market that are backed by said trials. Plandaí, on the other hand, has committed to undertaking human clinical trials on all of its products to ensure the consumer receives what they believe they've purchased."

This, of course, leaves manufacturers who are currently using green tea extract in their products with a better option, and Plandaí's sales and marketing team can exploit the results of its clinical trial as a proven option that benefits its customer's end user.

About Stock Market Media Group

SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Research Reports, CEO Interview and Feature Articles. SMMG is compensated $3,500 per month by Plandai Biotechnology for content development. Previously, SMMG was compensated for similar content by a third party which occurred from April 2013 through June 2014. During that period, SMMG received approximately $55,000 for its content. Neither SMMG nor anyone associated with it owns shares in PLPL. For more information:

Contact Information